Inhibition of Hydroxymethylglutaryl-Coenzyme A Reductase Reduces Th1 Development and Promotes Th2 Development

Circulation Research

Volumn 93, Issue 10, 2003, Pages 948-956

  Hakamada Taguchi, Rie ^a   Uehara, Yoshio ^a   Kuribayashi, Kagemasa ^b   Numabe, Atsushi ^c   Saito, Kanako ^b   Negoro, Hideyuki ^a   Fujita, Toshiro ^a   Toyo Oka, Teruhiko ^a   Kato, Takuma ^b  

^a UNIVERSITY OF TOKYO   (Japan)

^b MIE UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c DOKKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

3 hydroxy 3 methylglutaryl coenzyme A reductase inhibitors; Glomerular sclerosis; Inflammation; Statins; Th1 Th2

Indexed keywords

ALBUMIN; ANTIBODY; ATORVASTATIN; CD3 ANTIGEN; CD4 ANTIGEN; CERIVASTATIN; FREUND ADJUVANT; GAMMA INTERFERON; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVALONIC ACID; MEVINOLIN; PRAVASTATIN; SIMVASTATIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN PRESENTING CELL; ARTICLE; CELL MATURATION; CELL POLARITY; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFECT; DRUG MECHANISM; DRUG POTENCY; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INHIBITION; EXPERIMENTAL MODEL; FEMALE; GLOMERULOSA CELL; GLOMERULOSCLEROSIS; GROWTH INHIBITION; IMMUNIZATION; INFLAMMATION; KIDNEY INJURY; LYMPH NODE CELL; MOUSE; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN TARGETING; PROTEINURIA; REGULATORY MECHANISM; T LYMPHOCYTE; TH1 CELL; TH2 CELL;

ANIMALS; ANTIGENS, CD; ANTIGENS, CD80; ANTIGENS, CD86; APOPTOSIS; CD4-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; COCULTURE TECHNIQUES; CYTOKINES; ENZYME INHIBITORS; FEMALE; HISTOCOMPATIBILITY ANTIGENS CLASS II; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYDROXYMETHYLGLUTARYL-COA-REDUCTASES, NADP-DEPENDENT; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; PYRIDINES; SPLEEN; TH1 CELLS; TH2 CELLS;

EID: 0344013648     PISSN: 00097330     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.RES.0000101298.76864.14     Document Type: Article

References (37)

1. Abbas AK, Murphy KM, Sher A. Functional diversity of helper T lymphocytes. Nature. 1996;383:787-793.
2. + T cell responses: the alternative approaches. Annu Rev Immunol. 1997;15:297-322.
3. Romagnani S. Th1 and Th2 in human diseases. Clin Immunol Immunopathol. 1996;80:225-235.
4. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;19;344:1383-1389.
5. Takemoto M, Liao JK. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Arterioscler Thromb Vasc Biol. 2001;21:1712-1719.
6. Koh KK. Effects of statins on vascular wall: vasomotor function, inflammation, and plaque stability. Cardiovasc Res. 2000;47:648-657.
7. Ridker PM, Rifai N, Clearfield M, Downs JR, Weis SE, Miles JS, Gotto AM Jr, for the Air Force/Texas Coronary Atherosclerosis Prevention Study Investigators. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med. 2001;28;344:1959-1965.
8. Kwak B, Mulhaupt F, Myit S, Mach F. Statins as a newly recognized type of immunomodulator. Nat Med. 2000;6:1399-1402.
9. Weitz-Schmidt G, Welzenbach K, Brinkmann V, Kamata T, Kallen J, Bruns C, Cottens S, Takada Y, Hommel U. Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat Med. 2001;7:687-692.
10. Youssel S, Stuve O, Patarroyo JC, Rulz PJ, Radosevich JL, Hur EM, Bravo M, Mitchell DJ, Sobel RA, Steinman L, Zamvil SS. The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature. 2002;420:78-84.
11. Aktas O, Waiczies S, Smorodchenko A, Dorr J, Seeger B, Prozorvski T, Sallach S, Endres M, Brocke S, Nitsch R, Zipp F. Treatment of relapsing paralysis in experimental encephalomyelitis by targeting Th1 cells through atorvastatin. J Exp Med. 2003;197:725-733.
12. Leung BP, Sattar N, Crilly A, Prach M, McCarey DW, Payne H, Madhok R, Campbell C, Gracie JA, Liew FY, McInnes IB. A novel antiinflammatory role for simvastatin in inflammatory arthritis. J Immunol. 2003;170:1524-1530.
13. + T cells. Eur J Immunol. 1998;28:865-873.
14. + T cells toward the Th1 subset by CTLA-4 costimulation. J Immunol. 2000;164:3554-3562.
15. Uehara Y, Kawabata Y, Hirawa N, Takada S, Nagata T, Numabe A, Iwai J, Sugimoto T. Possible radical scavenging properties of cicletanine and renal protection in Dahl salt sensitive rats. Am J Hypertens. 1993;6:463-472.
16. Numabe A, Ara N, Hakamada-Taguchi R, Suzuki N, Hirawa N, Kawabata Y, Negoro T, Nagata T, Goto A, Toyo-oka T, Fujita T, Uehara Y. Effects of anti-platelet aggregation drug dilazep on cognitive function in Dahl salt sensitive rats. Hypertens Res. 2003;26:185-191.
17. + T cell-intrinsic mechanism. J Exp Med. 1998;188:2289-2299.
18. Sayegh MH, Akalin E, Hancock WW, Russell ME, Carpenter CB, Linsley PS, Turka LA. CD28-B7 blockade after alloantigenic challenge in vivo inhibits Th1 cytokines but spares Th2. J Exp Med. 1995;181:1869-1874.
19. Stuber E, Strober W, Neurath M. Blocking the CD40L-CD40 interaction in vivo specifically prevents the priming of T helper 1 cells through the inhibition of interleukin 12 secretion. J Immunol. 1996;183:693-698.
20. Karulin AY, Hesse MD, Yip HC, Lehmann PV. Indirect IL-4 pathway in type 1 immunity. J Immunol. 2002;168:545-553.
21. Farrar JD, Asnagli H, Murphy KM. T helper subset development: roles of instruction, selection, and transcription. J Clin Invest. 2002;109:431-435.
22. Ortego M, Bustos C, Hernandez-Presa MA, Tunon J, Diaz C, Hernandez G, Egido J. Atorvastatin reduces NF-κB activation and chemokine expression in vascular smooth muscle cells and mononuclear cells. Atherosclerosis. 1999;147:253-261.
23. Aronica MA, Mora AL, Mitchell DB, Finn PW, Johnson JE, Sheller JR, Boothby MR. Preferential role for NF-κB/Rel signaling in the type 1 but not type 2 T cell-dependent immune response in vivo. J Immunol. 1999;163:5116-5124.
24. Balamuth F, Leitenberg D, Unternaehrer J, Mellman I, Bottomly K. Distinct patterns of membrane microdomain partitioning in Th1 and Th2 cells. Immunity. 2001;15:729-738.
25. Gubina E, Chen T, Zhang L, Lizzio EF, Kozlowski S. CD43 polarization in unprimed T cells can be dissociated from raft coalescence by inhibition of HMG CoA reductase. Blood. 2002;99:2518-2525.
26. Salomon B, Bluestone JA. LFA-1 interaction with ICAM-1 and ICAM-2 regulates Th2 cytokine production. J Immunol. 1998;161:5138-5142.
27. Yip HC, Karulin AY, Tary-Lehmann M, Hesse MD, Radeke H, Heeger PS, Trezza RP, Heinzel FP, Forsthuber T, Lehmann PV. Adjuvant-guided type-1 and type-2 immunity: infectious/noninfectious dichotomy defines the class of response. J Immunol. 1999;162:3942-3949.
28. + T cells recognizing specific antigen deposited in glomeruli cause glomerulonephritis-like kidney injury. Clin Immunol. 2002;104:161-173.
29. + T cells specific to a glomerular basement membrane antigen mediate glomerulonephritis. J Clin Invest. 2002;109:517-524.
30. Huang XR, Tipping PG, Shuo L, Holdsworth SR. Th1 responsiveness to nephritogenic Ags determines susceptibility to crescentic glomerulonephritis in mice. Kidney Int. 1997;51:94-103.
31. Oda H, Keane WF. Recent advances in statins and the kidney. Kidney Int. 1999;56:S2-S5.
32. Kim SY, Guijarro C, O'Donnell MP, Kasiske BL, Kim Y, Keane WF. Human mesangial cell production of monocyte chemoattractant protein-1: modulation by lovastatin. Kidney Int. 1995;48:363-371.
33. O'Donnnell MP, Kasiske BL, Kim Y, Atluru D, Keane WF. Lovastatin inhibits proliferation of rat mesangial cells. J Clin Invest. 1993;91:83-87.
34. Grandaliano G, Biswas P, Choudhury GG, Abboud HE. Simvastatin inhibits PDGF-induced DNA synthesis in human glomerular mesangial cells. Kidney Int. 1993;44:503-508.
35. Vrtovsnik F, Couette S, Prie D, Lallemand D, Friedlander G. Lovastatin-induced inhibition of renal epithelial tubular cell proliferation involves a p21ras activated, AP-1-dependent pathway. Kidney Int. 1993;44:503-508.
36. Rogler G, Lackner KJ, Schmitz G. Effects of fluvastatin on growth of porcine and human vascular smooth muscle cells in vitro. Am J Cardiol. 1995;76:114A-116A.
37. Munro E, Patel M, Cha P, Betteridge L, Clunn G, Gallagher K, Hughes A, Schachter M, Wolfe J, Sever P. Inhibition of human vascular smooth muscle cell proliferation by lovastatin: the role of isoprenoid intermediates of cholesterol synthesis. Eur J Clin Invest. 1994;24:766-772.